A detailed history of Daiwa Securities Group Inc. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 535 shares of VIR stock, worth $4,622. This represents 0.0% of its overall portfolio holdings.

Number of Shares
535
Previous 535 -0.0%
Holding current value
$4,622
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

BUY
$19.96 - $28.22 $838 - $1,185
42 Added 8.52%
535 $14,000
Q2 2022

Aug 09, 2022

BUY
$19.08 - $26.7 $2,117 - $2,963
111 Added 29.06%
493 $13,000
Q4 2021

Feb 03, 2022

SELL
$30.97 - $54.03 $2,013 - $3,511
-65 Reduced 14.54%
382 $16,000
Q3 2021

Nov 05, 2021

BUY
$34.9 - $54.54 $6,770 - $10,580
194 Added 76.68%
447 $19,000
Q1 2021

May 03, 2021

BUY
$26.34 - $83.07 $342 - $1,079
13 Added 5.42%
253 $13,000
Q4 2020

Feb 04, 2021

BUY
$25.51 - $43.38 $6,122 - $10,411
240 New
240 $6,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.15B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.